Posted by AGORACOM-JC
at 5:28 PM on Thursday, August 5th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
” The HPQ NANO team is now more confident than ever that the PUREVAPTM NSiR will be able to deliver, at scale, and on-demand, a nano silicon for anode production that will be cost competitive. The validation announced today …. was the big breakthrough we were looking for”
Peter Pascali, President and CEO of technology partner PyroGenesis added a little more excitement when he stated:
“Words cannot adequately describe the excitement at PyroGenesis at potentially being able to address and solve challenges in developing lithium-ion batteries, which are sought after by many industries but specifically the EV market.”
Using an analogy to describe the importance of this milestone, $HPQ CEO Bernard Tourillon stated it was equivalent to the first SpaceX successful landing of its Falcon rocket. Specifically, though he was confident in their ability to produce Nano Silicon, actually producing it now removes all doubt and the Company can now focus on:
“… Subsequent batches will be delivered to the awaiting automobile manufacturers plus numerous other entities that have demonstrated an interest in receiving samples.“
Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!
Posted by AGORACOM-JC
at 4:13 PM on Tuesday, August 3rd, 2021
Intema Solutions (ITM:TSXV) an emerging esports and iGaming company that is creating an Esports adventure like no other …. Create the world’s foremost esports and iGaming ecosystem.
The global online gambling market could potentially hit $1 TRILLION by the end of this decade. The obvious reasons include the following:
Exponential growth in the number of people online. Yet only 59% of the world means more to come.
Fast growth in the number of countries and jurisdictions legalizing gambling to collect tax revenue.
Esports was already the fastest growing sub-sector of digital entertainment, and Covid 19 has only accelerated this trend.
Biggest brands/tournament prizes / online audiences in the world … 500M +
The International Olympic Committee has recognized esports as a sport, and it will be a medal event at the 2022 Asian Games
Despite the vast amount of viewers, esports is still dramatically under-monetized relative to traditional sports. ITM believes wagering will play a major role in helping monetize this ever evolving platform.
Now sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, discuss the art and science of psychedelic trip-sitting.
Gaining insurance coverage for off-label ketamine treatment of depression could help exponentially more people in their healing journeys. Off-label medicine isn’t covered by insurance.
“Our health care system does acknowledge and allow us to use medicines off-label. Probably 20 percent or more of all prescriptions are given that way.” – Novamind Chief Medical Officer Dr. Reid Robison
We are pleased to announce the completed the construction of a new clinic focused on integrative psychiatric care and clinical research in Draper, Utah. With the opening of the New Clinic, Novamind is on track to open four new locations in Utah by September 2021, doubling the size of its network to eight clinics.
“We are on a mission to reduce suffering and optimize wellness and are committed to shaping the future of psychedelic medicine in a responsible and accessible way,” said Dr. Reid Robison, Novamind’s Chief Medical Officer.
In an article for Harvard Health, Peter Grinspoon, MD, covers how psychedelics work, evidence for using psychedelics medicinally and the pros and cons. It’s an interesting read given his personal history with psychedelics, which dates back to when he was 14 and reading “Psychedelic Drugs Reconsidered.” He remembers the book urging “an open-minded reappraisal about the therapeutic potential of this class of drugs.” Anyone involved in psychedelics knows that not all conversations on the topic are open-minded. It’s why part of the mission to provide safe, legal access to psychedelics also includes an educational component. The more we can destigmatize psychedelics, the faster we can continue to push the renaissance forward.
Have you ever wondered what psychedelic therapy looks like? This article provides an insight into that process. “You don’t just get thrown into it,” (Jennifer) Mitchell says. “It’s not Burning Man or something. It’s very thoughtful.” And it’s something we take very seriously at our Cedar Psychiatry clinics. We recently posted a blog about psychedelics and safety considerations. Read it here.
Posted by AGORACOM-JC
at 4:07 PM on Thursday, July 29th, 2021
How do you connect over 100M small businesses in China who need access to different kinds of credit …. with 1000’s of banks and lending institutions that have different lending criteria?
Well, if you try to do it the old fashioned way, you just can’t. This forces SMB’s (small and medium businesses) and lenders to deal within local markets, which drastically reduces alternatives, competition and ultimately business …. while leaving both sides with a daunting, slow and inefficient manual workload.
ENTERS PEAK FINTECH
The Peak Fintech Lending Hub uses Artificial Intelligence and analytics to fully automate the process by which lenders and borrowers connect quickly and match perfectly across several market verticals.
The Lending Hub ecosystem helped facilitate approximately CAD$2.24B worth of transactions since 2018, with approximately 31 000 SMEs in the ecosystem
When CEO Johnson Joseph says this AI-Powered platform is revolutionizing the Chinese SMB commercial lending ecosystem, it isn’t just lip service … Peak Fintech is delivering results:
Q1 Financial Highlights:
Total revenue of $14,239,776
Adjusted EBITDA* of $121,737
Revenue Projections:
$105 MILLION Revenue Projected This Year
$305M 2022
$625M 2023
+
NASDAQ within 3 weeks
M&A + ⏫ $$ Revisions
Watch this powerful interview with Peak Fintech CEO Johnson Joseph.
Chief Medical Officer Dr. Reid Robison explains the three pillars of Ketamine therapy and the steps we take to prevent misuse.
“I’ve never had a client who we’ve done the appropriate process with who has entered into a troubled relationship with ketamine through the course of their treatment.”
Our Chief Medical Officer joins Health Professional Radio to discuss psychedelic medicine and our rapid expansion phase as we grow our network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine.
“We’re expanding even more with the need that has come up through the pandemic and the willingness to look towards new and improved ways of approaching our mental health”
We are pleased to announce that we have submitted our application to have our common shares posted for trading on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“Having the Company’s common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind’s mental health and psychedelic medicine business,” said Yaron Conforti, CEO and Director of Novamind.
A groundbreaking Yale study has uncovered a new dimension in understanding how psychedelics affect us: with small, physical changes to the brain. The study tracked how psilocybin, the active molecule in psychedelic mushrooms, not only has significant and long-lasting effects on mood but actually stimulates growth of new neuronal connections within the brain.
Governments around the world accelerated the clinical research process to develop vaccines for the Covid-19 health crisis. So why can’t we do the same for drugs to treat the mental health crisis? Monnica Williams and Morgan Campbell argue the point in the Baltimore Sun, comparing the investment in mental health treatment with physical health treatment: Investment in psychiatric therapies has remained very low compared to the burden of diseases, with $1.80 per $1,000 in disease burden for major depression and $0.40 for bipolar disorder compared to $9.40 for COPD, $7.60 for diabetes and $75.50 for cancer.
The popularity of using ketamine as a psychedelic treatment is only growing, according to ABC News. Less than 60 ketamine clinics existed in the United States in 2015. In 2018, that number climbed to over 300. With over 7,000 ketamine treatments to date, Novamind remains one of the busiest and most experienced ketamine practices in America.
Michael Pollan, the award-winning journalist who wrote “How to Change Your Mind,” a comprehensive examination of psychedelics history and his personal experience, is back. His new book contrasts the effects of three plant-based substances: caffeine, opium and mescaline. His section on mescaline further destigmatizes psychedelics through a critical and journalistic lens.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
Posted by AGORACOM-JC
at 4:54 PM on Friday, July 16th, 2021
Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:
If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.
Posted by AGORACOM-JC
at 4:10 PM on Friday, July 16th, 2021
FOBI AI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement for enterprise level retailers.
More than just lip service, these are just a sample of the major milestones reached by $FOBI over the past 9 months:
Strategic Alliance with global data leader – NeilsonIQ – to “Transform Retail Sector”
A partnership with NTT DATA, a top-ranked global IoT services company, and subsidiary of Nippon Telegraph and Telephone, the world’s 4th largest telecom company, ranked 55th In Fortune Global 500.
Approved for Oracle Partner Network
Pilot Projects with Sobeys, TELUS, Certas and other national level retailers
Multi-Year Direct Seller Agreement With TELUS, in which TELUS resells FOBI solutions to national business customers
Posted by AGORACOM-JC
at 5:47 PM on Tuesday, July 13th, 2021
PyroGenesis is the world leader in the development of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world that significantly reduce both greenhouse gases and costs of doing business for some of the world’s biggest companies in these following verticals:
Ultra High-Tech 3D Printing (Additive Manufacturing)
Iron Ore Pelletization
Aluminum Smelters Recovery Of Dross
High-Purity Silicon For EV Batteries
….. More
Today, PyroGenesis CEO Peter Pascali provides investors with a comprehensive update of each vertical and some of the major business developments taking place within each of them. Watch our great interview with CEO Peter Pascali
Posted by AGORACOM-JC
at 4:06 PM on Monday, July 12th, 2021
As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada.
This is comprised of awarded and not executed work, made up of a combination of service contracts and project work in both HVAC Building Automation and Mechanical lines of business.
We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about their multimillion-dollar backlog. Check out the full interview below.
